Circulating tumor DNA (ctDNA) is a powerful diagnostic companion to tissue profiling.
Tumor fraction (TF) is a global assessment of an individual's ctDNA burden.
We evaluated the impact of plasma TF on mutation detection and clinical outcomes in patients with previously treated, advanced NSCLC on Lung-MAP.
